Memorial Sloan Kettering Cancer Center announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with a state-of-the-art outpatient medical facility to be known as The David H. Koch Center for Cancer Care. The new center will provide the most advanced cancer treatments in a dynamic space designed with the needs of patients firmly in mind.
Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.
Positive results from a clinical trial published in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.
Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.
Memorial Sloan Kettering Cancer Center (MSK) has debuted MyMSK, a new mobile application. The app, compatible with iPad, iPhone, and all iOS devices, allows MSK patients to quickly and easily access their lab and radiology results, view their upcoming appointments, record their medications and symptoms in online diaries, communicate with their healthcare team, and more.
In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health is funding a research collaboration among six institutions in close alliance. The total funding, provided by the National Institute of Allergy and Infectious Diseases, could be up to $45.7 million over seven years.